MAURIZIO DE ANGELIS / SCIENCE PHOTO LIBRARY MAURIZIO DE ANGELIS / SCIENCE PHOTO LIBRARY
Computer illustration of a low-density lipoprotein (LDL, 'bad' cholesterol) molecule (round) bound to an LDL receptor (LDLR) protein (orange) in the wall of a blood vessel (not to scale), with a molecule of the enzyme proprotein convertase subtilisin/kexin type 9 (PCSK9, blue) bound to a PCSK9 inhibitor antibody (green). When there are high levels of LDL cholesterol in the blood it builds up on the sides of blood vessels hardening them, a condition named atherosclerosis. This narrows the blood vessels and may block them. LDL receptors recognise and bind to LDL molecules to remove them from the bloodstream. When PCSK9 binds to an LDLR, the receptor is destroyed along with the LDL particle. But if PCSK9 does not bind, the receptor can return to the surface of the cell and remove more cholesterol. Monoclonal antibodies that bind to and inhibit PCSK9 are being used to reduce the amount of cholesterol in the blood by improving the liver's ability to recycle LDLRs.
Model release not required. Property release not required.